Health care stocks rose Monday afternoon, with the NYSE Health Care Index adding 2% and the Health Care Select Sector SPDR Fund (XLV) up 2.1%.
The iShares Biotechnology ETF (IBB) rose 0.7%.
In corporate news, Walgreens Boots Alliance (WBA) shares fell 6.4% after CNBC's David Faber reported the company's talks with Sycamore Partners on a go-private deal are "mostly dead," according to media reports.
Sage Therapeutics (SAGE) said Monday its board rejected Biogen's (BIIB) unsolicited, non-binding proposal to buy Sage shares not already owned by Biogen for $7.22 per share. Sage shares rose 4.8% and Biogen was adding 1.8%.
Allakos (ALLK) said Monday its phase 1 trial of AK006 in chronic spontaneous urticaria failed to demonstrate therapeutic efficacy and that its development will be terminated immediately. Its shares dropped 78%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。